AIM ImmunoTech (AIM) EBT (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly EBT came in at -$3.2 million in Q1 2026, up 15.49% YoY from -$2.8 million in Q1 2025, and little changed on a QoQ basis from -$3.2 million in Q4 2025.
AIM ImmunoTech (AIM) EBT (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of EBT data on file, last reported at -$3.2 million in Q1 2026.
- Quarterly EBT rose 15.49% year-over-year to -$3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.0 million (up 32.69% YoY) and the FY2025 annual result came in at -$58.5 million, up 6.6% from the prior year.
- EBT steadied at -$3.2 million in Q1 2026, from -$3.2 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$2.6 million in Q3 2025 to a low of -$14.1 million in Q4 2023.
- A 5-year average of -$5.7 million and a median of -$4.9 million in 2025 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT plunged 151.04% — and 2024, when it soared 57.66%.
- Tracing AIM's EBT over 5 years: stood at -$5.6 million in 2022, then sank by 151.04% to -$14.1 million in 2023, then surged by 57.66% to -$6.0 million in 2024, then jumped by 45.98% to -$3.2 million in 2025, then gained by 0.31% to -$3.2 million in 2026.
- The last three EBT figures came in at -$3.2 million (Q1 2026), -$3.2 million (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | AIM ImmunoTech | 4.34 Mn | -5.62 Mn | 21,000.00 | -3.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.13 Mn |
| Mar 31, 2026 | -3.22 Mn |
| Dec 31, 2025 | -3.23 Mn |
| Sep 30, 2025 | -2.64 Mn |
| Jun 30, 2025 | -4.94 Mn |
| Mar 31, 2025 | -3.82 Mn |
| Dec 31, 2024 | -5.99 Mn |
| Sep 30, 2024 | -4.71 Mn |
| Jun 30, 2024 | -6.33 Mn |
| Mar 31, 2024 | -8.31 Mn |
| Dec 31, 2023 | -14.14 Mn |
| Sep 30, 2023 | -8.36 Mn |
| Jun 30, 2023 | -5.66 Mn |
| Mar 31, 2023 | -4.50 Mn |
| Dec 31, 2022 | -5.63 Mn |
| Sep 30, 2022 | -6.76 Mn |
| Jun 30, 2022 | -4.86 Mn |
| Mar 31, 2022 | -3.34 Mn |
| Dec 31, 2021 | -7.45 Mn |
| Sep 30, 2021 | -5.07 Mn |